Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report.
Intrathecal chemotherapy has been the mainstay treatment for meningeal carcinomatosis for decades. However, this has not been the case with non-small cell lung cancer (NSCLC), due to the low efficacy of the drugs that could be used before. Gemcitabine is an effective drug against NSCLC and has a structure similar to cytarabine, which has been widely used in intrathecal chemotherapy. Thus, intrathecal gemcitabine chemotherapy might prove to be suitable for leptomeningeal carcinomatosis induced by NSCLC. We herein report our experience using gemcitabine intrathecal injections in a NSCLC patient with leptomeningeal carcinomatosis.
Chen
Yuh-Min
YM
Chest Department, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Shih-pai Road, 112, ROC, Taipei, Taiwan. ymchen@vghtpe.gov.tw
Chen
Mei-Chun
MC
Tsai
Chun-Ming
CM
Perng
Reury-Perng
RP
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007278:Injections, Spinal; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine